Dexamethasone - Comprehensive Research Paper

Document Information

• Paper Number: 51 of 76
• Category: Corticosteroids - Glucocorticoids (Long-Acting)
• Last Updated: 2025-12-26
• Status: FDA-APPROVED (since 1958)

1. Summary

Dexamethasone is a potent, long-acting synthetic glucocorticoid with approximately 25-30 times the anti-inflammatory potency of hydrocortisone. Distinguished by its complete absence of mineralocorticoid activity and prolonged duration of action (36-54 hours), dexamethasone occupies a unique therapeutic niche among corticosteroids. FDA-approved on October 30, 1958, it has become a cornerstone in the treatment of cerebral edema, as part of chemotherapy regimens, for fetal lung maturation, and most recently as life-saving therapy for severe COVID-19.

The 2020 RECOVERY trial established dexamethasone as the first treatment proven to reduce mortality in hospitalized COVID-19 patients requiring supplemental oxygen, fundamentally changing pandemic treatment protocols worldwide. This landmark finding highlighted dexamethasone's potent immunomodulatory properties in controlling the cytokine storm associated with severe viral pneumonia.

Key Distinguishing Features:

• Highest potency among commonly used oral corticosteroids (25-30x hydrocortisone)
• No mineralocorticoid activity - minimal sodium/fluid retention
• Long-acting - biological half-life 36-54 hours allows once-daily or less frequent dosing
• Crosses placenta in active form - ideal for fetal lung maturation
• Potent antiemetic - standard in chemotherapy-induced nausea/vomiting protocols

Key Characteristics:

• Generic Name: Dexamethasone
• Brand Names: Decadron, DexPak, Hemady, Neofordex (multiple myeloma), various ophthalmic/otic brands
• FDA Approval: October 30, 1958
• Drug Class: Synthetic glucocorticoid corticosteroid (long-acting)
• Potency Ratio: 25-30:1 anti-inflammatory vs. hydrocortisone
• Mineralocorticoid Activity: None (0)
• Equivalent Dose: 0.75 mg = 5 mg prednisone = 20 mg hydrocortisone
• Half-Life: Plasma ~4 hours; biological 36-54 hours
• Controlled Substance: No
• Pregnancy Category: C
• Available Formulations: Oral tablets, oral solution, injectable, ophthalmic, otic

Primary Clinical Applications:

• Cerebral edema (tumor-associated, traumatic)
• COVID-19 (hospitalized patients requiring oxygen)
• Fetal lung maturation (preterm delivery risk)
• Chemotherapy-induced nausea and vomiting (CINV)
• Multiple myeloma (combination therapy)
• Acute lymphoblastic leukemia
• Adrenocortical suppression testing (Cushing's diagnosis)
• Inflammatory and allergic conditions
• Altitude sickness prophylaxis and treatment

Goal Relevance:

• Reduce inflammation and swelling for conditions like arthritis or after injury
• Manage severe COVID-19 symptoms and improve survival rates in hospitalized patients
• Support fetal lung development in cases of preterm delivery risk
• Alleviate nausea and vomiting associated with chemotherapy treatments
• Control cerebral edema related to brain tumors or traumatic injuries
• Aid in the treatment of multiple myeloma as part of combination therapy
• Provide relief from altitude sickness symptoms during high-altitude travel or activities

Goal Archetype Integration

Corticosteroid Classification Profile

Dexamethasone represents the pure glucocorticoid archetype - maximum anti-inflammatory potency with zero mineralocorticoid activity. This profile makes it the preferred agent when:

• Fluid retention must be avoided (cerebral edema, heart failure patients)
• Maximum potency is required (severe inflammation, oncology protocols)
• Precise hormonal effects are needed (diagnostic suppression testing)

Potency-Duration Matrix

Goal-Specific Applications

Anti-Inflammatory Goals:

• Pure glucocorticoid effect without fluid complications
• Ideal for CNS inflammation (no added edema)
• Preferred in patients with hypertension or heart failure

Diagnostic Goals:

• Gold standard for HPA axis assessment (dexamethasone suppression test)
• No mineralocorticoid confounding of results
• Consistent, predictable suppression kinetics

Oncology Goals:

• Anti-emetic protocols (CINV prevention)
• Multiple myeloma combination therapy
• Lymphocytic malignancy induction

Obstetric Goals:

• Crosses placenta in active form (unlike prednisone)
• Fetal lung maturation acceleration
• Not inactivated by placental 11-beta-HSD2

Why No Mineralocorticoid Activity Matters

The 16-alpha-methyl group on dexamethasone eliminates binding to the mineralocorticoid receptor. Clinical implications:

1. No sodium retention - Critical for cerebral edema management
2. No potassium wasting (direct mineralocorticoid effect) - Though indirect glucocorticoid effects on kidney still exist
3. No fluid retention - Preferred in edematous states
4. Cleaner diagnostic testing - No aldosterone-like confounding

Age-Stratified Dosing

Pediatric Dosing (0-17 years)

Croup (Acute Laryngotracheobronchitis):

• Dose: 0.6 mg/kg as single dose
• Maximum: 10-16 mg
• Route: Oral preferred; IM if unable to swallow
• May repeat: Once if needed after 24 hours
• Evidence: Strong; reduces hospitalization and return visits

Asthma Exacerbation:

• Dose: 0.6 mg/kg/day
• Maximum: 16 mg/day
• Duration: 1-2 days (equivalent efficacy to 5-day prednisone)
• Evidence: Non-inferior to 5-day prednisone courses

Chemotherapy-Induced Nausea (Pediatric Oncology):

• Dose: 5-10 mg/m2 (varies by protocol)
• Maximum: 20 mg
• Timing: Day 1 of chemotherapy; may continue for delayed emesis

COVID-19 (Hospitalized, Oxygen-Requiring):

• Dose: 0.15 mg/kg once daily
• Maximum: 6 mg
• Duration: Up to 10 days
• Note: Only for hypoxic patients; no benefit without oxygen requirement

Growth Considerations:

• Linear growth suppression with chronic use
• Monitor height velocity at each visit
• Catch-up growth typically occurs after discontinuation
• Use lowest effective dose for shortest duration

Adult Dosing (18-64 years)

Standard Adult Dosing Ranges:

Geriatric Dosing (65+ years)

Age-Related Considerations:

• Increased sensitivity to glucocorticoid effects
• Higher baseline risk for adverse effects
• Start with lower doses when possible

Recommended Modifications:

Enhanced Monitoring for Elderly:

• Blood glucose: Check daily during treatment
• Cognitive status: Delirium screening at each encounter
• Bone health: DEXA if therapy >3 months anticipated
• Fall risk: Assess myopathy; consider PT evaluation
• Potassium: Check at baseline and weekly

Specific Geriatric Risks:

• Delirium: Higher incidence; consider dose reduction if occurs
• Glucose: More pronounced hyperglycemia; insulin often required
• Bone: Accelerated osteoporosis in already-at-risk population
• Infection: Attenuated immune response; lower threshold for workup
• Myopathy: Proximal weakness increases fall risk

Weight-Based vs Fixed Dosing

Pediatric: Always weight-based (mg/kg) Adult: Generally fixed doses for most indications Obese Adults: Consider ideal body weight for weight-based calculations

COVID-19 Specific:

• RECOVERY trial used fixed 6 mg regardless of weight
• No evidence that weight-based dosing improves outcomes
• Fixed 6 mg is standard of care

2. Mechanism of Action

Dexamethasone exerts its effects primarily through glucocorticoid receptor activation, with the same fundamental mechanism as other corticosteroids but with greater potency and duration.

Glucocorticoid Receptor Binding

High-Affinity Binding:

• Dexamethasone has high affinity for the glucocorticoid receptor (GR)
• Synthetic fluorination at C9 increases receptor binding and metabolic stability
• Methylation at C16 eliminates mineralocorticoid activity
• These structural modifications create a highly potent, pure glucocorticoid

Nuclear Translocation:

1. Dexamethasone crosses cell membranes (lipophilic)
2. Binds cytoplasmic glucocorticoid receptor (GR-α)
3. Receptor-drug complex releases heat shock proteins
4. Complex translocates to nucleus
5. Binds glucocorticoid response elements (GREs) on DNA
6. Modulates gene transcription

Genomic Effects

Transactivation (Gene Induction):

• Anti-inflammatory proteins:
  • Lipocortin-1 (inhibits phospholipase A2)
  • IκBα (inhibits NF-κB)
  • MAPK phosphatase-1
  • IL-10
  • Gluconeogenic enzymes

Transrepression (Gene Suppression):

• Pro-inflammatory mediators:
  • Cytokines: IL-1β, IL-2, IL-6, TNF-α, IFN-γ
  • Chemokines: IL-8, MCP-1, RANTES
  • Inflammatory enzymes: COX-2, iNOS, PLA2
  • Adhesion molecules: ICAM-1, VCAM-1, E-selectin

NF-κB Inhibition:

• Direct interaction with NF-κB subunits
• Prevention of NF-κB DNA binding
• Induction of IκBα (sequesters NF-κB)
• Major mechanism of anti-inflammatory action

COVID-19 Mechanism (2024 Research)

Monocyte Modulation:

• 2024 Cell journal study revealed mechanism in severe COVID-19
• Dexamethasone reverses transcriptional hallmarks of monocyte dysregulation
• Induces specific monocyte substate with glucocorticoid-response gene expression
• Effects detected in both circulating and pulmonary monocytes
• Molecular responses directly linked to improved survival
• Demonstrates immunomodulation beyond simple immunosuppression

Cytokine Storm Suppression:

• Inhibits hyperinflammatory response
• Reduces destructive cytokine effects
• Preserves antiviral immune function at appropriate doses
• Timing critical: Beneficial only in hyperinflammatory phase

Non-Genomic Effects

Rapid Actions:

• Membrane-associated GR signaling
• Ion channel modulation
• Second messenger effects
• Occur within minutes (before gene transcription changes)
• Relevant in high-dose/acute settings

Metabolic Effects

Glucose Metabolism:

• Potent induction of gluconeogenesis
• Peripheral insulin resistance
• Marked hyperglycemic effect (diabetogenic)

Protein Metabolism:

• Protein catabolism
• Muscle wasting with prolonged use
• Negative nitrogen balance

Lipid Metabolism:

• Lipolysis promotion
• Fat redistribution (central)
• May alter lipid profiles

Bone Metabolism:

• Inhibits osteoblast function
• Reduces calcium absorption
• Potent osteoporosis risk with chronic use

Absence of Mineralocorticoid Effects

Clinical Significance:

• No sodium retention
• No potassium wasting (direct effect)
• No fluid retention
• Preferred when mineralocorticoid effects undesirable:
  • Cerebral edema (no additional edema)
  • Heart failure patients
  • Hypertensive patients

3. FDA-Approved Indications

Dexamethasone has FDA approval for numerous conditions, reflecting its broad anti-inflammatory and immunosuppressive properties.

Endocrine Disorders

Primary Indications:

• Primary adrenocortical insufficiency (adjunct, not first-line)
• Secondary adrenocortical insufficiency
• Congenital adrenal hyperplasia
• Nonsuppurative thyroiditis
• Hypercalcemia of malignancy

Diagnostic Use:

• Dexamethasone suppression test for Cushing's syndrome
• Low-dose test: 1 mg overnight
• High-dose test: 8 mg overnight or 2 mg q6h x 48 hours

Rheumatic Disorders

Primary Indications:

• Rheumatoid arthritis (acute flares)
• Psoriatic arthritis
• Ankylosing spondylitis
• Acute gouty arthritis
• Systemic lupus erythematosus
• Dermatomyositis, polymyositis
• Acute bursitis, tenosynovitis

Allergic States

Primary Indications:

• Severe allergic reactions, anaphylaxis (adjunct)
• Angioedema
• Drug hypersensitivity reactions
• Serum sickness

Dermatologic Diseases

Primary Indications:

• Pemphigus
• Bullous dermatitis herpetiformis
• Severe erythema multiforme
• Exfoliative dermatitis
• Severe psoriasis

Respiratory Diseases

Primary Indications:

• COVID-19 (hospitalized patients requiring supplemental oxygen)
• Sarcoidosis
• Fulminating/disseminated tuberculosis (with anti-TB therapy)
• Aspiration pneumonitis
• Asthma (severe exacerbations)
• Croup (acute laryngotracheobronchitis)

Cerebral Edema

Critical Indication:

• Brain tumors (primary or metastatic)
• Post-craniotomy edema
• Traumatic brain injury
• Spinal cord compression (malignant)

Dosing for Cerebral Edema:

• Initial: 10 mg IV followed by 4 mg IM/IV every 6 hours
• Taper over 7 days

Hematologic/Neoplastic Diseases

Primary Indications:

• Multiple myeloma (key component of many regimens)
• Acute lymphoblastic leukemia (ALL)
• Hodgkin and non-Hodgkin lymphoma
• Idiopathic thrombocytopenic purpura (ITP)
• Autoimmune hemolytic anemia

Gastrointestinal Diseases

Primary Indications:

• Ulcerative colitis (acute severe)
• Crohn's disease (acute severe)

Fetal Lung Maturation

Critical Obstetric Indication:

• Threatened preterm delivery (24-34 weeks gestation)
• Alternative to betamethasone
• Accelerates fetal lung surfactant production

ACOG Recommended Dosing:

• 6 mg IM every 12 hours for 4 doses (total 24 mg)

Chemotherapy-Induced Nausea and Vomiting (CINV)

Standard Component:

• Part of antiemetic regimens for highly emetogenic chemotherapy
• Often combined with 5-HT3 antagonists and NK1 antagonists
• Single doses: 8-20 mg on day of chemotherapy

Altitude Sickness

Prophylaxis and Treatment:

• High-altitude cerebral edema (HACE)
• High-altitude pulmonary edema (HAPE)
• Prophylaxis: 4 mg every 6-12 hours
• Treatment HACE: 8 mg initially, then 4 mg every 6 hours

Ophthalmic Conditions (Topical)

With appropriate ophthalmic formulations:

• Allergic conjunctivitis
• Anterior uveitis
• Post-operative inflammation

4. Dosing and Administration

Dexamethasone dosing varies widely based on indication, with its high potency requiring careful attention to equivalent dosing.

Dosage Forms

Oral Tablets:

• 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg

Oral Solution:

• 0.5 mg/5 mL, 1 mg/mL (Dexamethasone Intensol)

Injectable:

• Dexamethasone sodium phosphate: 4 mg/mL, 10 mg/mL (IV/IM)
• Other concentrations available

Ophthalmic:

• 0.1% solution/suspension

Otic:

• Various combination products

Dose Equivalency

Condition-Specific Dosing

COVID-19 (RECOVERY Trial Protocol):

• 6 mg once daily (oral or IV)
• Duration: Up to 10 days
• Only for patients requiring supplemental oxygen
• Not recommended for patients not requiring oxygen

Cerebral Edema:

• Initial: 10 mg IV bolus
• Followed by: 4 mg IM/IV every 6 hours
• Taper over 5-7 days once response achieved
• May use oral once stable

Fetal Lung Maturation:

• 6 mg IM every 12 hours x 4 doses
• Total course: 24 mg over 48 hours
• Single course recommended (repeat courses controversial)

Multiple Myeloma (Examples):

• VD (bortezomib/dexamethasone): 20-40 mg weekly
• VRd regimen: 40 mg on days 1, 8, 15
• Varies by protocol

CINV (Chemotherapy Antiemetic):

• Highly emetogenic chemo: 12-20 mg on day 1
• Moderately emetogenic: 8-12 mg
• May continue 8 mg daily for delayed emesis prevention

Croup (Pediatric):

• 0.6 mg/kg single dose (max 10-16 mg)
• May repeat x 1 if needed

Altitude Sickness:

• Prophylaxis: 2 mg every 6 hours or 4 mg every 12 hours
• Treatment HACE: 8 mg initially, then 4 mg every 6 hours
• Begin on ascent; continue for 2-3 days at altitude

Adrenal Suppression Testing:

• Overnight: 1 mg at 11 PM; measure AM cortisol
• Low-dose: 0.5 mg every 6 hours x 48 hours
• High-dose: 2 mg every 6 hours x 48 hours

Administration

Oral:

• May take with food to reduce GI upset
• Once-daily dosing usually sufficient (long half-life)
• Morning dosing preferred for non-suppressive uses

Intravenous:

• Dexamethasone sodium phosphate for IV use
• May give as IV push or infusion
• Compatible with common IV fluids

Intramuscular:

• Deep IM injection
• Used for fetal lung maturation
• Depot effect from IM administration

Tapering

When Required:

• After >2-3 weeks of therapy
• May need slower tapers than shorter-acting agents due to potent HPA suppression
• Some short-course uses (CINV, croup) don't require taper

Considerations:

• Very potent HPA axis suppression
• Consider equivalent prednisone dose when designing taper
• Convert to shorter-acting steroid for taper if preferred

5. Pharmacokinetics

Dexamethasone's pharmacokinetic profile is characterized by excellent oral bioavailability, longer duration of action, and hepatic metabolism.

Absorption

Oral Bioavailability:

• Excellent; approximately 70-80%
• Dose-proportional between 0.5-40 mg

Time to Peak (Tmax):

• Oral: Median 1 hour (range 0.5-4 hours)
• IM: 1-2 hours (dexamethasone sodium phosphate)

Food Effects:

• Minimal impact on absorption
• May take with food to reduce GI upset

Distribution

Protein Binding:

• Approximately 77% bound to plasma proteins
• Less protein binding than cortisol (which binds transcortin)
• Primarily binds to albumin

Volume of Distribution:

• Widely distributed
• Crosses blood-brain barrier (important for cerebral edema)
• Crosses placenta in active form (important for fetal lung maturation)
• Enters breast milk

Placental Transfer:

• Unlike prednisone/prednisolone, NOT significantly inactivated by placental 11β-HSD2
• Reaches fetus in active form
• This property makes it suitable for antenatal corticosteroid therapy

Metabolism

Hepatic Metabolism:

• Metabolized by CYP3A4
• Produces inactive metabolites
• Subject to CYP3A4 drug interactions

Metabolites:

• 6β-hydroxydexamethasone (major)
• Other hydroxylated metabolites
• All inactive

Elimination

Plasma Half-Life:

• Mean terminal half-life: ~4 hours (range 3-4.5 hours)
• Longer than prednisone/prednisolone

Biological Half-Life:

• 36-54 hours
• Classified as long-acting corticosteroid
• Allows once-daily or less frequent dosing

Excretion:

• Renal: <10% unchanged in urine
• Primarily eliminated as metabolites

Comparison of Half-Lives

Special Populations

Hepatic Impairment:

• Metabolized by CYP3A4
• May have prolonged effect in severe liver disease
• Consider dose reduction

Renal Impairment:

• Minimal renal excretion of parent drug
• No routine dose adjustment required

Pediatric:

• Similar pharmacokinetics to adults
• Weight-based dosing

Geriatric:

• May have increased sensitivity
• Start with lower doses

Drug Interactions (Pharmacokinetic)

CYP3A4 Inducers (Decrease Dexamethasone Effect):

• Rifampin (most significant)
• Phenytoin, phenobarbital, carbamazepine
• May require dose increase

CYP3A4 Inhibitors (Increase Dexamethasone Effect):

• Ketoconazole, itraconazole
• Ritonavir
• Clarithromycin
• May require dose reduction

6. Side Effects and Adverse Reactions

Dexamethasone shares the adverse effect profile of all corticosteroids but with enhanced intensity due to its high potency. The absence of mineralocorticoid activity reduces some complications.

Common Side Effects (>10%)

Metabolic:

• Hyperglycemia (very common, often requiring treatment)
• Weight gain
• Increased appetite
• Fluid retention (despite no mineralocorticoid activity - glucocorticoid effect)

Psychiatric:

• Insomnia (very common with high doses)
• Mood changes, euphoria
• Irritability, restlessness
• Anxiety

Gastrointestinal:

• Dyspepsia, heartburn
• Nausea
• Increased appetite
• Abdominal distension

Dermatologic:

• Facial flushing
• Skin thinning
• Easy bruising
• Acne

Serious Adverse Reactions

Adrenal Suppression:

• Very potent HPA axis suppression
• Occurs with therapy >2-3 weeks
• May persist for months after discontinuation
• Risk of adrenal crisis with abrupt withdrawal or stress

Immunosuppression:

• Increased infection risk
• Masked signs of infection
• Reactivation of latent infections (TB, herpes, strongyloides)
• Opportunistic infections

Musculoskeletal:

• Osteoporosis (significant risk with chronic use)
• Osteonecrosis (avascular necrosis)
• Myopathy, proximal muscle weakness
• Growth suppression in children

Cardiovascular:

• Hypertension
• Thromboembolism risk
• Arrhythmias (with high doses)

Metabolic/Endocrine:

• Diabetes mellitus induction or worsening
• Cushingoid features (moon face, buffalo hump, central obesity)
• Hyperlipidemia
• Hypokalemia (from increased renal potassium excretion)

Ophthalmologic:

• Posterior subcapsular cataracts
• Glaucoma
• Central serous chorioretinopathy

Neuropsychiatric:

• Steroid psychosis (high doses)
• Depression
• Mania
• Cognitive impairment

Gastrointestinal:

• Peptic ulcer disease
• GI bleeding
• Pancreatitis

COVID-19-Specific Considerations

Increased Mortality in Mild Disease:

• RECOVERY trial: No benefit (potential harm) in non-oxygen-requiring patients
• May impair viral clearance in early disease
• Use only in hospitalized patients with hypoxia

Hyperglycemia Management:

• Common in COVID-19 patients on dexamethasone
• May require insulin even in non-diabetics
• Monitor glucose frequently

High-Dose/Oncologic Considerations

Multiple Myeloma Regimens:

• Weekly high doses (40 mg) well-tolerated short-term
• Psychiatric effects common
• GI prophylaxis recommended
• Glucose monitoring essential

Tumor Lysis Syndrome:

• Monitor in hematologic malignancies
• Adequate hydration critical

Duration-Related Risk

7. Drug Interactions

Dexamethasone has numerous clinically significant drug interactions, particularly involving CYP3A4 metabolism and hormonal pathways critical to optimization protocols.

Growth Hormone and Peptide Interactions (Critical for Optimization Protocols)

Glucocorticoids, particularly potent agents like dexamethasone, directly antagonize growth hormone secretion and action through multiple mechanisms. This interaction is clinically significant for patients using GH secretagogues or optimization protocols.

Mechanism of GH Suppression:

1. Direct Pituitary Suppression:

   • Glucocorticoids suppress GHRH (growth hormone-releasing hormone) signaling
   • Reduce somatotroph responsiveness to GHRH and ghrelin
   • Increase somatostatin tone (GH-inhibiting hormone)

2. Peripheral GH Resistance:

   • Reduce GH receptor expression in target tissues
   • Impair IGF-1 synthesis in liver
   • Block IGF-1 signaling at cellular level

3. Direct IGF-1 Suppression:

   • Glucocorticoids reduce hepatic IGF-1 production
   • May persist for days after dexamethasone discontinuation

Impact on Specific GH Peptides:

Timing Considerations:

Clinical Recommendations:

1. Avoid concurrent use of dexamethasone and GH peptides
2. Pause peptide protocols during dexamethasone therapy
3. Wait adequate washout before resuming GH secretagogues
4. Monitor IGF-1 after resuming peptides to confirm efficacy return
5. Consider alternative corticosteroids if steroid needed during peptide therapy:
   • Prednisone/prednisolone: Still suppressive but shorter duration
   • Hydrocortisone: Least suppressive; physiologic replacement doses may be tolerable

Exception - Diagnostic Use: The GH-suppressive effect of dexamethasone is intentionally used in provocative testing to assess GH reserve. This is separate from therapeutic considerations.

Testosterone and Androgen Interactions

Dexamethasone Effects on Androgens:

Clinical Implications for TRT Patients:

• Short-term dexamethasone: Minimal impact on exogenous testosterone efficacy
• Chronic use: May require dose adjustment; monitor symptoms and labs
• DHEA supplementation may be needed with prolonged therapy

Thyroid Hormone Interactions

Effects on Thyroid Axis:

• Suppresses TSH secretion
• Inhibits T4 to T3 conversion (reduced deiodinase activity)
• May lower total T4 and T3 (reduced TBG)
• Free T4 usually maintained in short-term use

Monitoring:

• Check TSH and free T4 if prolonged therapy
• May require thyroid dose adjustment in hypothyroid patients
• Allow 4-6 weeks after dexamethasone cessation before assessing thyroid function

CYP3A4-Related Interactions

CYP3A4 Inducers (Decrease Dexamethasone Effect):

CYP3A4 Inhibitors (Increase Dexamethasone Effect):

Dexamethasone as CYP3A4 Inducer

Dexamethasone Induces CYP3A4:

• At high doses (20-40 mg), dexamethasone induces CYP3A4
• May reduce efficacy of CYP3A4 substrates:
  • Oral contraceptives (consider backup contraception)
  • Apixaban, rivaroxaban
  • Cyclosporine, tacrolimus
  • Many chemotherapy agents

Pharmacodynamic Interactions

Potassium-Depleting Drugs:

• Diuretics (thiazides, loop diuretics): Additive hypokalemia
• Amphotericin B: Severe hypokalemia risk
• Monitor potassium; supplement as needed

Anticoagulants:

• Warfarin: Variable effect (monitor INR closely)
• May enhance or reduce anticoagulant response
• DOACs: Dexamethasone may reduce levels via CYP3A4 induction

Diabetes Medications:

• Insulin: Increased requirements
• Oral hypoglycemics: Reduced efficacy
• Monitor glucose; adjust doses

NSAIDs/Aspirin:

• Increased GI bleeding risk
• Consider gastroprotection

Live Vaccines:

• Contraindicated during immunosuppressive doses
• Risk of disseminated infection

Cardiac Glycosides:

• Hypokalemia increases digoxin toxicity risk
• Monitor potassium and digoxin levels

Oncology-Specific Interactions

Multiple Myeloma:

• Thalidomide/lenalidomide: Increased thrombosis risk
• Bortezomib: Standard combination; monitor for neuropathy

Chemotherapy:

• Standard antiemetic component
• Monitor for interactions with specific regimens
• May affect chemotherapy metabolism

COVID-19 Treatment Interactions

Remdesivir:

• No significant interaction reported
• Used together safely in RECOVERY trial

Baricitinib (when combined):

• Additive immunosuppression
• Increased infection risk
• Close monitoring required

8. Contraindications

Absolute Contraindications

Hypersensitivity:

• Known hypersensitivity to dexamethasone or any formulation component
• Rare but documented
• Cross-reactivity with other corticosteroids possible

Systemic Fungal Infections:

• Untreated systemic fungal infections
• Dexamethasone may cause dissemination
• Exception: Specific protocols for fungal meningitis

Live Vaccines:

• During immunosuppressive therapy
• Risk of disseminated vaccine infection
• Exception: May be given to patients on physiologic replacement doses

Cerebral Malaria:

• Dexamethasone shown to worsen outcomes
• Contraindicated for this specific indication

Relative Contraindications

Active Infections:

• Active bacterial infections (without adequate coverage)
• Tuberculosis (latent or active, without appropriate anti-TB therapy)
• Herpes simplex keratitis (systemic therapy)
• Strongyloides (hyperinfection risk)

Gastrointestinal:

• Active peptic ulcer disease
• Recent GI surgery/anastomosis
• Diverticulitis
• GI perforation risk

Cardiovascular:

• Uncontrolled hypertension
• Recent myocardial infarction
• Heart failure (may worsen with fluid retention)

Metabolic:

• Uncontrolled diabetes mellitus
• Severe osteoporosis

Psychiatric:

• History of steroid psychosis
• Severe depression or psychotic disorders
• Use with extreme caution; close monitoring

Ophthalmologic:

• Primary open-angle glaucoma (topical)
• Herpes simplex keratitis (topical)

Warnings and Precautions

HPA Axis Suppression:

• Occurs rapidly with high-potency dexamethasone
• Stress-dose steroids needed during illness/surgery
• Gradual tapering required after prolonged use

Masking of Infection:

• Signs of infection may be suppressed
• High index of suspicion needed
• Opportunistic infections possible

Immunocompromised Patients:

• Avoid in severe immunosuppression unless benefits outweigh risks
• Close monitoring for infections

COVID-19 Timing:

• Only beneficial in hypoxic phase
• May harm if given too early
• Timing critical for benefit

9. Special Populations

Pregnancy

FDA Category: C (prior to 2015 classification)

Antenatal Use for Fetal Lung Maturity:

• Indicated for threatened preterm delivery (24-34 weeks)
• Dexamethasone crosses placenta in active form
• Not inactivated by placental 11β-HSD2 (unlike prednisone)
• ACOG regimen: 6 mg IM q12h x 4 doses
• Reduces RDS, IVH, NEC, and neonatal mortality
• Single course recommended; repeat courses controversial

Maternal Risks:

• Hyperglycemia
• Infection
• Delayed wound healing if cesarean delivery needed

Fetal Considerations:

• Slight reduction in birth weight
• Transient adrenal suppression
• Benefits clearly outweigh risks for preterm delivery

Non-Obstetric Uses in Pregnancy:

• Use only when benefits outweigh risks
• Consider hydrocortisone (less placental transfer) for maternal indications
• Dexamethasone for conditions requiring high potency

Lactation

Excretion:

• Excreted in breast milk
• Amount depends on dose and timing

Recommendations:

• Compatible with breastfeeding at low doses
• High doses: Consider timing feeds (4 hours after dose)
• Monitor infant for growth and development
• Avoid chronic high-dose therapy

Pediatric Use

Approved Uses:

• Croup: 0.6 mg/kg single dose (up to 10-16 mg)
• Cerebral edema
• Chemotherapy antiemesis
• Various inflammatory conditions

Special Considerations:

• Growth suppression with chronic use
• Monitor linear growth closely
• Catch-up growth usually occurs after discontinuation
• Use lowest effective dose for shortest duration

COVID-19 in Children:

• RECOVERY trial included children
• Same 6 mg (or 0.15 mg/kg, max 6 mg) daily dosing

Geriatric Use

Increased Sensitivity:

• Enhanced glucocorticoid effects
• Start with lower doses

Specific Risks:

• Accelerated bone loss (already at risk)
• Increased infection susceptibility
• Glucose intolerance
• Cognitive effects (delirium risk)
• Falls risk from myopathy

Monitoring:

• More frequent glucose monitoring
• Bone density considerations
• Cognitive status assessment

Hepatic Impairment

Metabolism:

• CYP3A4 metabolized
• Prolonged effect in severe liver disease

Dosing:

• Consider dose reduction in severe impairment
• No specific guidelines; clinical judgment
• Monitor for enhanced effects

Renal Impairment

Elimination:

• <10% renally eliminated as parent drug
• Metabolites renally excreted

Dosing:

• No routine dose adjustment required
• Hemodialysis: Not significantly removed
• Use standard doses; monitor response

Diabetic Patients

Effects:

• Potent hyperglycemic effect
• May unmask latent diabetes
• Worsens glycemic control in diabetics

Management:

• Expect increased insulin/medication requirements
• Monitor glucose frequently (multiple daily)
• Adjust diabetes medications proactively
• Short courses: Temporary increases usually needed

10. Monitoring Parameters

Baseline Assessments

Before Initiating Therapy:

• Blood glucose (fasting preferred)
• Blood pressure
• Electrolytes (especially potassium)
• Complete blood count
• Hepatic function tests
• Lipid profile (if chronic therapy anticipated)
• Bone density (DEXA) if chronic use anticipated
• Eye examination if prolonged use expected
• Screen for latent TB if risk factors
• Assess mental health history

During Therapy

Short-Term Use (≤2 weeks):

• Blood glucose (daily in hospitalized patients)
• Blood pressure
• Monitor for GI symptoms
• Mental status assessment

Intermediate Therapy (2-4 weeks):

• All short-term parameters
• Electrolytes (potassium)
• Signs/symptoms of infection
• Weight

Chronic Therapy (>4 weeks):

COVID-19 Monitoring (Hospitalized)

Daily:

• Oxygen saturation
• Blood glucose (often multiple times daily)
• Signs of secondary infection
• Clinical response

As Indicated:

• Repeat inflammatory markers
• Cultures if infection suspected
• Mental status

Oncology Setting

Multiple Myeloma/Chemotherapy:

• Glucose before and during high-dose days
• GI symptom assessment
• Thromboprophylaxis compliance
• Psychiatric assessment

Discontinuation Monitoring

Tapering Period:

• Signs of adrenal insufficiency
• Return of underlying disease
• Withdrawal symptoms (myalgia, arthralgia, fatigue)

Post-Discontinuation:

• Monitor for adrenal insufficiency for months
• Stress-dose steroids if illness/surgery occurs
• Gradual return of HPA axis function

Specific Clinical Scenarios

Cerebral Edema:

• Neurologic status
• Intracranial pressure signs
• Taper feasibility

Fetal Lung Maturation:

• Maternal glucose
• Signs of infection
• Fetal well-being

Bloodwork Impact and Suppression Testing

Dexamethasone Suppression Testing (Diagnostic Use)

Dexamethasone is the gold standard agent for evaluating HPA axis function and diagnosing Cushing's syndrome due to its potent, predictable cortisol suppression without mineralocorticoid confounding.

Overnight Dexamethasone Suppression Test (1 mg DST)

Protocol:

1. Administer dexamethasone 1 mg orally at 11:00 PM
2. Draw serum cortisol at 8:00 AM the following morning
3. Patient should be fasting for cortisol draw

Interpretation:

False Positives (Failure to Suppress):

• Obesity (especially visceral)
• Depression and psychiatric illness
• Alcoholism
• Medications (phenytoin, phenobarbital, rifampin - CYP3A4 inducers)
• Estrogen therapy (increases CBG)
• Acute illness or stress
• Shift workers (disrupted circadian rhythm)

False Negatives (Inappropriate Suppression):

• Mild Cushing's syndrome
• Cyclic Cushing's (tested during quiescent phase)
• Recent glucocorticoid use (exogenous suppression)

Low-Dose Dexamethasone Suppression Test (2-Day Protocol)

Protocol:

1. Baseline: 24-hour urine free cortisol and/or serum cortisol
2. Dexamethasone: 0.5 mg every 6 hours for 48 hours (8 doses total)
3. Collection: 24-hour urine during second day; serum cortisol 6 hours after last dose

Interpretation:

• Normal: Serum cortisol <1.8 mcg/dL; urine free cortisol <10 mcg/24h
• Cushing's syndrome: Failure to suppress

High-Dose Dexamethasone Suppression Test (Differential Diagnosis)

Purpose: Differentiate pituitary Cushing's (Cushing's disease) from ectopic ACTH and adrenal tumors

Protocol (Overnight):

1. Baseline serum cortisol at 8:00 AM
2. Dexamethasone 8 mg orally at 11:00 PM
3. Repeat serum cortisol at 8:00 AM

Protocol (2-Day):

1. Baseline 24-hour urine free cortisol
2. Dexamethasone 2 mg every 6 hours for 48 hours
3. Repeat 24-hour urine on day 2

Interpretation:

Note: High-dose DST has limited sensitivity/specificity; often supplemented with inferior petrosal sinus sampling.

Impact on Routine Bloodwork

Hormonal Markers:

Metabolic Markers:

Inflammatory Markers:

Timing Recommendations for Accurate Labs

If Patient Has Received Dexamethasone:

For Optimization Protocol Labs:

• Pause dexamethasone at least 5-7 days before comprehensive hormone panels
• For ACTH stimulation testing, wait 4-6 weeks after courses >2 weeks
• Document any recent steroid use on lab requisition

Protocol Integration

Diagnostic Protocol Uses

Cushing's Syndrome Workup

Step 1 - Screening:

• Overnight 1 mg DST (most practical outpatient test)
• Alternative: 24-hour urine free cortisol, late-night salivary cortisol

Step 2 - Confirmation:

• Low-dose 2-day DST if overnight test borderline
• Repeat 24-hour urine free cortisol

Step 3 - Differential Diagnosis:

• Plasma ACTH (suppressed = adrenal; elevated = pituitary or ectopic)
• High-dose DST (>50% suppression suggests pituitary)
• CRH stimulation test
• Inferior petrosal sinus sampling (definitive for pituitary vs ectopic)

Step 4 - Localization:

• MRI pituitary (if ACTH-dependent)
• CT adrenals (if ACTH-independent)
• CT chest/abdomen (if ectopic ACTH suspected)

Adrenal Incidentaloma Evaluation

When adrenal mass discovered incidentally:

1. Overnight 1 mg DST to assess autonomous cortisol secretion
2. Plasma metanephrines (rule out pheochromocytoma)
3. Aldosterone/renin if hypertensive (rule out Conn's)

Subclinical Cushing's Interpretation:

• Failure to suppress on 1 mg DST without overt Cushing's features
• Associated with increased cardiovascular risk
• Consider surgical referral for unilateral adenomas

Anti-Emetic Protocol Integration (CINV)

Highly Emetogenic Chemotherapy (HEC) Protocols

NCCN/ASCO Guideline-Based Regimen:

Day 1 (Chemotherapy Day):

• Dexamethasone 12-20 mg IV/PO (given 30 minutes before chemo)
• NK1 antagonist (aprepitant 125 mg or fosaprepitant 150 mg IV)
• 5-HT3 antagonist (ondansetron 8-16 mg or palonosetron 0.25 mg)
• +/- Olanzapine 10 mg PO (optional)

Days 2-4 (Delayed Emesis Prevention):

• Dexamethasone 8 mg PO once daily
• Aprepitant 80 mg PO days 2-3 (if using 3-day regimen)
• +/- Olanzapine 10 mg PO daily

AC (Anthracycline/Cyclophosphamide) Regimen - Special Case:

• Considered highly emetogenic due to delayed emesis risk
• Full HEC antiemetic protocol recommended

Moderately Emetogenic Chemotherapy (MEC) Protocols

Day 1:

• Dexamethasone 8-12 mg IV/PO
• 5-HT3 antagonist
• Consider NK1 antagonist for carboplatin-based regimens

Days 2-3:

• Dexamethasone 8 mg PO daily OR
• 5-HT3 antagonist PRN

Low Emetogenic Chemotherapy (LEC)

• Dexamethasone 8 mg single dose OR
• 5-HT3 antagonist single dose
• PRN dosing often sufficient

Optimization Protocol Integration

When Dexamethasone is Medically Necessary

Managing Conflicts with HRT/Peptide Protocols:

Scenario 1: Short-term dexamethasone needed (CINV, croup, allergic reaction)

• Pause GH peptides during therapy
• Continue TRT (exogenous testosterone unaffected)
• Resume peptides 5-7 days after last dexamethasone dose
• No thyroid adjustment typically needed for short courses

Scenario 2: Medium-term dexamethasone (1-4 weeks)

• Pause all GH secretagogues
• Monitor for testosterone symptoms; adjust TRT dose if needed
• Check IGF-1 before resuming peptides
• Assess HPA recovery with morning cortisol before resuming optimization labs

Scenario 3: Chronic dexamethasone requirement

• GH peptides contraindicated during therapy
• Consider switch to shorter-acting steroid if possible
• Comprehensive endocrine evaluation before resuming optimization protocols
• ACTH stimulation test may be needed to assess adrenal recovery

Integration with Specific Protocols

BPC-157/TB-500 (Healing Peptides):

• Dexamethasone may actually enhance healing in acute inflammatory phase
• However, chronic use impairs tissue repair
• Short course dexamethasone compatible; chronic use counterproductive

Thymosin Alpha-1 (Immune Modulation):

• Dexamethasone is immunosuppressive; TA-1 is immunomodulatory
• Generally avoid concurrent use unless specifically indicated
• May consider sequential use (dexamethasone for acute inflammation, TA-1 for immune support after)

NAD+ Precursors:

• No direct interaction
• May continue during dexamethasone therapy

Metformin:

• Dexamethasone counteracts metabolic benefits
• Expect glucose elevation; may need to increase metformin temporarily
• Monitor closely; consider insulin if glucose uncontrolled

Peri-Procedural Protocol

For Patients on Optimization Protocols Needing Surgery:

Pre-operative:

• Continue TRT through surgery
• Pause GH peptides 24-48 hours before (GH may affect wound healing dynamics)
• If dexamethasone used as surgical anti-emetic: standard single dose acceptable

Intra-operative:

• Dexamethasone 4-8 mg IV commonly used for PONV prevention
• Single dose has minimal impact on optimization protocols

Post-operative:

• Resume GH peptides when oral intake established (typically 3-5 days)
• If prolonged steroid course required, follow Scenario 2 above
• Monitor wound healing; dexamethasone may impair if prolonged

Special Situations

COVID-19 in Optimization Protocol Patients

If hospitalized with hypoxic COVID-19:

• Dexamethasone 6 mg x 10 days is life-saving; prioritize this
• Pause all GH peptides
• Continue TRT (may actually support recovery)
• Resume optimization labs 4-6 weeks after hospitalization
• ACTH stimulation may be needed before resuming comprehensive protocols

Altitude Exposure

For patients using GH peptides planning high-altitude travel:

• Dexamethasone prophylaxis will block peptide effects
• Options:
  • Accept reduced peptide efficacy during altitude exposure
  • Use acetazolamide instead (does not block GH)
  • Pause peptides during altitude stay; resume on return

11. Cost and Availability

Generic Availability

Generic Status:

• Generic dexamethasone widely available since patent expiration (1980s)
• Multiple manufacturers in US and worldwide
• Extremely affordable generic option

Cost:

• Among the least expensive corticosteroids
• 4 mg tablets: Approximately $0.10-0.50 per tablet (generic)
• Injectable (4 mg/mL): Approximately $1-5 per vial (generic)
• Oral solution: Approximately $10-30 per bottle

Brand Name Products

Oral Formulations:

Injectable:

• Dexamethasone sodium phosphate: Multiple generics
• Very affordable ($1-10 per vial)

Ophthalmic:

• Maxidex (0.1% suspension): $$-$$$
• Generic 0.1% available: $

Insurance Coverage

Coverage Status:

• Generic dexamethasone universally covered
• First-tier formulary placement typical
• No prior authorization for standard uses
• Specialty products (Hemady) may require PA

COVID-19:

• Widely covered for hospitalized patients
• WHO essential medicine designation

International Availability

WHO Essential Medicine:

• Listed on WHO Model List of Essential Medicines
• Available in virtually every country
• Extremely affordable in global context

Regional Availability:

• United States: Widely available
• Europe: Widely available (including Neofordex for myeloma)
• Developing countries: Generally available, very affordable
• No significant supply issues historically

Formulation Availability

Oral:

• Tablets: 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg
• Solution: 0.5 mg/5 mL, 1 mg/mL (Intensol)
• Elixir: Available in some markets

Parenteral:

• Dexamethasone sodium phosphate: 4 mg/mL, 10 mg/mL, 20 mg/mL
• Available for IV, IM, and various injection routes

Topical/Local:

• Ophthalmic: 0.1% solution and suspension
• Otic: Combination products
• Implants: Ozurdex (intravitreal)

Supply Chain Considerations

COVID-19 Impact:

• Initial surge in demand during 2020
• Supply chain adapted quickly
• No sustained shortages
• Generic availability ensured adequate supply

Manufacturing:

• Multiple global manufacturers
• Robust supply chain
• No single-source vulnerability

12. Clinical Evidence Summary

Landmark Clinical Trials

RECOVERY Trial (COVID-19) - 2020:

• Design: Open-label RCT; 2,104 dexamethasone vs 4,321 usual care
• Population: Hospitalized COVID-19 patients
• Intervention: Dexamethasone 6 mg daily for up to 10 days
• Primary Outcome: 28-day mortality
• Key Results:
  • Overall mortality reduction: 22.9% vs 25.7% (RR 0.83, p<0.001)
  • Mechanical ventilation: 29.3% vs 41.4% (RR 0.64)
  • Oxygen without ventilation: 23.3% vs 26.2% (RR 0.82)
  • No oxygen: No benefit (17.8% vs 14.0%)
• Impact: First treatment proven to reduce COVID-19 mortality; changed global practice

CRASH Trial (Head Injury) - 2004:

• Finding: High-dose corticosteroids increased mortality in traumatic brain injury
• Implication: Dexamethasone NOT indicated for routine TBI
• Exception: Tumor-associated edema still appropriate

Antenatal Corticosteroids - Multiple Trials:

• Liggins & Howie (1972): Original proof of concept
• Crowley Cochrane Review: Meta-analysis confirming benefits
• Results: Reduces RDS by ~50%, IVH by ~50%, neonatal mortality by ~30%
• Standard of Care: ACOG/SMFM recommended since 1994

Systematic Reviews and Meta-Analyses

COVID-19 Meta-Analysis (WHO REACT Working Group, 2020):

• 7 RCTs, 1,703 patients
• All-cause mortality: OR 0.66 (95% CI: 0.53-0.82)
• Consistent benefit across corticosteroid types
• Dexamethasone most extensively studied

CINV Prevention:

• Multiple meta-analyses confirm dexamethasone as standard component
• Adds significant antiemetic efficacy to 5-HT3 antagonists
• Standard in NCCN, ASCO, MASCC guidelines

Cerebral Edema (Tumor):

• Observational evidence primarily
• Dramatic clinical responses documented
• Standard of care for brain tumor edema for decades

Key Efficacy Data by Indication

Multiple Myeloma:

• Dexamethasone component of all modern regimens
• VRd (bortezomib/lenalidomide/dex) is standard first-line
• Dexamethasone contributes to anti-myeloma activity
• 40 mg weekly dosing standard in most protocols

Croup:

• Single-dose dexamethasone highly effective
• Reduces return visits, hospitalizations
• Superior to nebulized epinephrine alone
• 0.6 mg/kg now standard of care

Altitude Sickness:

• Effective for prevention and treatment of HACE
• Adjunct for HAPE treatment
• Evidence from high-altitude studies

Guidelines Incorporation

COVID-19:

• WHO: Strong recommendation for severe/critical COVID-19
• NIH: Recommended for hospitalized patients requiring oxygen
• UK NICE: Recommended per RECOVERY trial protocol

Oncology:

• NCCN: Standard in CINV prophylaxis
• IMWG: Component of myeloma regimens
• Standard in ALL induction protocols

Obstetrics:

• ACOG: Alternative to betamethasone for fetal lung maturity
• WHO: Recommended for preterm birth risk

Ongoing Research

Post-COVID Investigations:

• Optimal timing of initiation
• Duration of therapy
• Combination with other immunomodulators

Oncology:

• Optimal dosing in novel combinations
• Steroid-sparing approaches where possible
• Managing toxicity in elderly patients

13. Comparison with Alternatives

Comparison with Other Corticosteroids

When to Choose Dexamethasone

Advantages:

• Highest potency (for severe inflammation)
• No mineralocorticoid effects (edema, heart failure)
• Long half-life (once-daily dosing)
• Crosses placenta (fetal lung maturity)
• Proven COVID-19 mortality benefit
• Potent antiemetic effect (CINV)
• Excellent for cerebral edema

Disadvantages:

• Very potent HPA suppression
• Not ideal for physiologic replacement
• Marked hyperglycemic effect
• May be excessive for mild conditions

Specific Comparisons

Dexamethasone vs Prednisone:

• Dexamethasone: More potent, longer-acting, no mineralocorticoid
• Prednisone: More commonly used for chronic inflammatory conditions
• Prednisone preferred for: Rheumatoid arthritis, asthma maintenance, PMR
• Dexamethasone preferred for: Cerebral edema, CINV, COVID-19, oncology

Dexamethasone vs Betamethasone:

• Virtually equivalent potency and duration
• Both cross placenta in active form
• Betamethasone preferred by some for antenatal use (more data)
• Dexamethasone: More versatile dosing forms

Dexamethasone vs Methylprednisolone:

• Methylprednisolone: Intermediate potency, IV pulse therapy
• Dexamethasone: Higher potency per mg
• MS relapses: Methylprednisolone traditional choice
• COVID-19: Dexamethasone has trial evidence

COVID-19 Corticosteroid Selection

RECOVERY Trial Evidence:

• Dexamethasone specifically studied and proven
• 6 mg daily = approximately 40 mg prednisone equivalent
• Other corticosteroids used if dexamethasone unavailable

Equivalent Regimens:

• Dexamethasone 6 mg = Prednisone 40 mg = Methylprednisolone 32 mg = Hydrocortisone 160 mg

Oncology Comparisons

Multiple Myeloma:

• Dexamethasone standard (high-dose protocols)
• No evidence prednisone equivalent effective
• Dexamethasone-specific anti-myeloma effects studied

CINV:

• Dexamethasone most studied and recommended
• Methylprednisolone also effective
• Dexamethasone preferred in guidelines

Fetal Lung Maturation

Dexamethasone vs Betamethasone:

• Both FDA-approved, both effective
• Betamethasone: More trials, single IM formulation
• Dexamethasone: Requires multiple doses, oral available
• ACOG considers both acceptable options
• Betamethasone slightly preferred historically

14. Storage and Handling

Oral Formulations

Tablets:

• Store at controlled room temperature (20-25°C / 68-77°F)
• Excursions permitted to 15-30°C (59-86°F)
• Protect from moisture
• Keep in original container with desiccant if provided
• Stable at room temperature for duration of shelf life

Oral Solution/Elixir:

• Store at controlled room temperature
• Protect from light
• Do not freeze
• Some formulations may require refrigeration after opening (check label)
• Intensol concentrate: Room temperature storage

Injectable Formulations

Dexamethasone Sodium Phosphate:

• Store at controlled room temperature (20-25°C / 68-77°F)
• Protect from light
• Do not freeze
• Stable in original packaging

After Dilution:

• Stable in D5W and NS for 24 hours at room temperature
• Stable for extended periods refrigerated
• Use within 24 hours for most clinical applications
• Visual inspection for particulates required

Compatibility:

• Compatible with most common IV fluids
• Y-site compatible with many medications
• Check specific compatibility for admixtures

Ophthalmic Formulations

Solutions/Suspensions:

• Store at 8-25°C (46-77°F)
• Some require refrigeration
• Protect from light
• Do not freeze
• Discard 28 days after opening (typical)

Handling:

• Avoid contamination of dropper tip
• Shake suspensions before use
• Wait 5 minutes between multiple eye drops

Stability Considerations

pH Sensitivity:

• Dexamethasone sodium phosphate stable in neutral pH
• Avoid highly acidic or basic conditions

Light Sensitivity:

• Protect from prolonged light exposure
• Amber vials provide protection
• Clear solutions preferred; discard if precipitate forms

Temperature:

• Room temperature storage for most formulations
• Avoid extreme heat
• Do not freeze solutions

Clinical Handling

COVID-19 Hospital Use:

• Standard room temperature storage
• IV or oral equally effective
• IV for patients unable to take oral

Fetal Lung Maturation:

• IM injection; standard storage
• Draw up immediately before administration
• No special handling requirements

Disposal

Pharmaceutical Waste:

• Dispose of according to institutional guidelines
• Not a controlled substance; standard disposal
• Take-back programs for patient disposal

Shelf Life

Typical Expiration:

• Tablets: 2-3 years from manufacture
• Injectable: 2-3 years from manufacture
• Oral solutions: 1-2 years; check after opening

Beyond-Use Dating:

• Compounded preparations: Per USP guidelines
• Diluted IV: Use within 24 hours typically

15. References

Primary Literature

1. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704.

2. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330-1341.

3. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;3(3):CD004454.

4. Kuo KN, Holloway WJ, Plotz PH. Dexamethasone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1979;26(2):276-283.

5. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98.

Clinical Guidelines

6. National Institutes of Health. COVID-19 Treatment Guidelines: Corticosteroids. https://www.covid19treatmentguidelines.nih.gov/

7. World Health Organization. Corticosteroids for COVID-19: Living Guidance. WHO/2019-nCoV/Corticosteroids/2020.1

8. American College of Obstetricians and Gynecologists. Antenatal Corticosteroid Therapy for Fetal Maturation. ACOG Committee Opinion No. 713. Obstet Gynecol. 2017;130:e102-109.

9. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782-2797.

10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 1.2024.

Pharmacology References

11. Chrousos GP. Glucocorticoid therapy. In: Jameson JL, et al., eds. Harrison's Principles of Internal Medicine. 21st ed. McGraw-Hill; 2022.

12. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.

13. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23-43.

Specialty References

14. Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol. 2005;23(9):2028-2037.

15. Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness: 2019 update. Wilderness Environ Med. 2019;30(4S):S3-S32.

16. Bjornson CL, Johnson DW. Croup in children. CMAJ. 2013;185(15):1317-1323.

Drug Information Resources

17. Dexamethasone. In: Lexicomp Online. Hudson, OH: Wolters Kluwer; 2024.

18. Dexamethasone. In: IBM Micromedex. Greenwood Village, CO: Truven Health Analytics; 2024.

19. Dexamethasone sodium phosphate [package insert]. Various manufacturers.

20. Hemady (dexamethasone) [package insert]. Cranford, NJ: Renaissance Lakewood LLC; 2021.

Document Metadata

Document Completion: 2025-12-26 Status: PAPER 51 OF 76 COMPLETE Next Paper: #52 - Methylprednisolone

This document is part of the comprehensive HRT/hormone therapy research paper series for clinical reference.